文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌消化内镜

幽门螺杆菌根除后胃癌风险分层与监测:2020年

Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020.
PubMed 文献 · Gastrointest Endosc · 2019-01-01

本文为述评,讨论幽门螺杆菌根除后胃癌风险分层与监测策略。引用Nam等对10,328名韩国健康体检者的回顾性研究:中位随访5.5年,根除幽门螺杆菌较持续感染者显著降低胃癌发生率(HR 0.29);萎缩性胃炎、胃癌家族史及可能较高的BMI为额外风险因素,低血清HDL水平与癌症风险显著增加相关(HR 2.67)。

要点

  • 根除幽门螺杆菌较持续感染显著降低胃癌发生率(HR 0.29)。
  • 萎缩性胃炎、胃癌家族史为重要风险因素,高BMI可能相关。
  • 低血清HDL水平与癌症风险显著增加相关(HR 2.67)。

核心结论

  • 根除幽门螺杆菌联合对高风险者的风险评估与监测项目,是当前减少胃癌死亡的最佳选择,以识别处于可治愈阶段的病变。

研究设计与样本

  • Nam等开展回顾性研究,纳入10,328名接受健康体检(含幽门螺杆菌检测-治疗项目)的韩国成人。
  • 中位随访时间5.5年。

主要发现

  • 根除幽门螺杆菌较持续感染者显著降低胃癌发生率(HR 0.29)。
  • 额外重要风险因素包括萎缩性胃炎、胃癌家族史,以及可能较高的BMI(在1个模型中显著、另1个模型不显著)。
  • 调整LDL水平及降脂药使用后,低血清HDL水平与癌症风险显著增加相关(HR 2.67)。

临床怎么用

  • 减少胃癌死亡的最佳当前选择是根除幽门螺杆菌联合针对高风险者的风险评估与监测项目,以识别可治愈阶段的病变。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastric cancer remains one of the most common causes of cancer deaths worldwide. The best current option for reducing gastric cancer deaths is Helicobacter pylori eradication combined with risk assessment and surveillance programs for those deemed to be at high risk for gastric cancer so as to identify lesions at a stage amenable to curative therapy. In this issue, Nam et al report a retrospective study of Helicobacter pylori eradication on gastric cancer incidence among 10,328 Korean adults undergoing health checkups including an H pylori test-and-treat program. With a median follow-up of time 5.5 years, they report that H pylori eradication resulted in a significant reduction of gastric cancer incidence in comparison with individuals with persistent infection (eg, hazard ratio [HR] 0.29). Additional important risk factors included atrophic gastritis, family history of gastric cancer, and possibly higher body mass index, which was significant in 1 model but not the other. They also noted that a low serum high-density lipoprotein (HDL) level was associated with a significant increased cancer risk (HR 2.67) when adjusted for low-density lipoprotein (LDL) level and use of lipid-lowering drug.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Tan MC, Graham DY. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020. Gastrointest Endosc. 2019. PMID: 31439130. doi:10.1016/j.gie.2019.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。